http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 12 May 2026 09:30:25 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Evaxion+to+present+EVX-04+leukemia+vaccine+data+at+EHA+2026+Congress/26474726.html <p>Evaxion A/S (NASDAQ: EVAX) will present new preclinical data for its EVX-04 therapeutic vaccine targeting acute myeloid leukemia at the European Hematology Association 2026 Congress in Stockholm, Sweden.</p> <p>The company will deliver a poster presentation on June 13, 2026, detailing the functional characterization of EVX-04, described as an off-the-shelf therapeutic vaccine for acute myeloid leukemia. The presentation is scheduled for 18:45-19:45 CET during poster session 2.</p> <p>EVX-04 was developed using Evaxion's AI-Immunology platform and targets endogenous retroviral antigens that are expressed in specific tumors but absent in normal tissue. The vaccine incorporates 16 endogenous retroviral fragments selected from five million potential candidates http://www.streetinsider.com/FDA/Evaxion+to+present+EVX-04+leukemia+vaccine+data+at+EHA+2026+Congress/26474726.html Tue, 12 May 2026 09:30:25 -0400 EVAX http://www.streetinsider.com/Press+Releases/Evaxion+to+present+new+data+for+EVX-04%2C+an+off-the-shelf+therapeutic+vaccine+for+acute+myeloid+leukemia%2C+at+the+EHA+2026+Congress/26474714.html <ul><li style="text-align:justify;"><b>Data will reflect the functional characterization of EVX-04</b></li><li style="text-align:justify;"><b>Poster presentation on June 13, 2026</b></li></ul> <p align="justify">COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the functional characterization of EVX-04, an off-the-shelf therapeutic acute myeloid leukemia (AML) vaccine, in a poster presentation at the European Hematology Association (EHA) 2026 Congress taking place in Stockholm, Sweden, June 11-14, 2026.</p> <p align="justify">The new preclinical data will represent another step towards clinical testing of EVX-04. Evaxion plans to submit a clinical trial application in the http://www.streetinsider.com/Press+Releases/Evaxion+to+present+new+data+for+EVX-04%2C+an+off-the-shelf+therapeutic+vaccine+for+acute+myeloid+leukemia%2C+at+the+EHA+2026+Congress/26474714.html Tue, 12 May 2026 09:30:00 -0400 EVAX http://www.streetinsider.com/Globe+Newswire/Evaxion+to+present+new+data+for+EVX-04%2C+an+off-the-shelf+therapeutic+vaccine+for+acute+myeloid+leukemia%2C+at+the+EHA+2026+Congress/26474714.html <ul><li style="text-align:justify;"><b>Data will reflect the functional characterization of EVX-04</b></li><li style="text-align:justify;"><b>Poster presentation on June 13, 2026</b></li></ul> <p align="justify">COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the functional characterization of EVX-04, an off-the-shelf therapeutic acute myeloid leukemia (AML) vaccine, in a poster presentation at the European Hematology Association (EHA) 2026 Congress taking place in Stockholm, Sweden, June 11-14, 2026.</p> <p align="justify">The new preclinical data will represent another step towards clinical testing of EVX-04. Evaxion plans to submit a clinical trial application in the http://www.streetinsider.com/Globe+Newswire/Evaxion+to+present+new+data+for+EVX-04%2C+an+off-the-shelf+therapeutic+vaccine+for+acute+myeloid+leukemia%2C+at+the+EHA+2026+Congress/26474714.html Tue, 12 May 2026 09:30:00 -0400 EVAX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+12/26474727.html si-local-file:///var/storage/secattach/20260512/26474727.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+12/26474727.html Tue, 12 May 2026 09:30:00 -0400 EVAX O.07609173 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+12/26474727.html si-local-file:///var/storage/secattach/20260512/26474727.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+12/26474727.html Tue, 12 May 2026 09:30:00 -0400 EVAX O.07609173 http://www.streetinsider.com/Earnings/Evaxion+Biotech+%28EVAX%29+Misses+Q1+EPS+by+1c/26448929.html <p>Evaxion Biotech (NASDAQ: EVAX) reported Q1 EPS of ($0.01).</p><p>For earnings history and earnings-related data on Evaxion Biotech (EVAX) <a href="http://www.streetinsider.com/ec_earnings.php?q=EVAX">click here</a>.</p> http://www.streetinsider.com/Earnings/Evaxion+Biotech+%28EVAX%29+Misses+Q1+EPS+by+1c/26448929.html Thu, 07 May 2026 08:06:51 -0400 EVAX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+07/26448453.html si-local-file:///var/storage/secattach/20260507/26448453.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+07/26448453.html Thu, 07 May 2026 07:40:00 -0400 EVAX O.07609173 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+07/26448453.html si-local-file:///var/storage/secattach/20260507/26448453.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+07/26448453.html Thu, 07 May 2026 07:40:00 -0400 EVAX O.07609173 http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Press+Releases/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html <p align="justify">COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results.</p> <p align="justify"><b>Business highlights (since last quarterly update)</b><br/>Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include:</p> <ul type="disc"><li>New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform’s precision in driving immune response. This marked our first milestone http://www.streetinsider.com/Globe+Newswire/Evaxion+announces+business+update+and+first+quarter+2026+financial+results/26448305.html Thu, 07 May 2026 07:30:00 -0400 A.09642568 A.35552990 A.50213909 EVAX O.00074346 O.07609173 O.20357061 O.20371933 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+04/26421562.html si-local-file:///var/storage/secattach/20260504/26421562.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evaxion+AS+++++++++++++++For%3A+May+04/26421562.html Mon, 04 May 2026 08:08:00 -0400 EVAX O.07609173